Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
Open Access
- 29 January 2022
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 11 (4) , 454-466
Abstract
Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat cholangiocarcinoma. A compartmental population pharmacokinetics model was developed using data from 318 patients with cancer enrolled in a phase 1 dose‐escalation/dose‐expansion study, a phase 1 Japanese PK bridging study, and a phase 2 cholangiocarcinoma study. The final model for pemigatinib was a 2‐compartment disposition model with first‐order absorption and linear elimination. All fixed‐ and random‐effect parameters were estimated with good precision, and no apparent biases in the overall model fit were observed. For females, the estimated typical pemigatinib absorption rate constant (ka) and oral clearance (CL/F) were estimated (1.49 L/h and 10.3 L/h, respectively). For males, the typical apparent clearance and ka are 19.0% higher and 56.5% lower, respectively, compared with females. Typical apparent volume of distribution of the central compartment (Vc/F) and peripheral compartment for a 73.3‐kg patient was estimated to be 122.0 L and 80.1 L, respectively; both increased with body weight. Phosphate binder coadministration decreases typical pemigatinib CL/F by 14.1%. Proton pump inhibitor coadministration increases typical pemigatinib apparent Vc/F by 24.4%. Phosphate binders and sex contribute a <20% change to CL/F. The impact of the investigated covariates on pemigatinib pharmacokinetics are not clinically significant.Keywords
This publication has 18 references indexed in Scilit:
- INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor modelsPLOS ONE, 2020
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2020
- Abstract C071: Pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignanciesMolecular Cancer Therapeutics, 2019
- Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2019
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinomaBritish Journal of Cancer, 2018
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaJournal of Clinical Oncology, 2018
- Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutationsCytokine & Growth Factor Reviews, 2015
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Targeting mutant fibroblast growth factor receptors in cancerTrends in Molecular Medicine, 2011
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009